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ABSTRACT

Catheters represent an essential part of the management of critically and
chronically ill patients. However, their use is often plagued by catheter related blood
stream infections (CRBSIs), which are associated with increased morbidity, hospital stay
and medical costs. Treatment for CRBSIs is often difficult due to the microorganism’s
development of resistance to the drug being used. Development of the resistance has been
directly correlated with the formation of biofilms, caused when bacteria adhere to the
surface of the catheters in community-like complexes. In order, to overcome antibiotic
resistance, chitosan nanoparticles encapsulating a biofilm degrading enzyme, β-NAcetylglucosaminidase (NAGase) were fabricated through an ionic gelation method.
Chitosan nanoparticle parameters; including, size, zeta potential, morphological
characteristics, swelling properties, encapsulation efficiencies and release profiles were
optimized for use as a biofilm degrading enzyme carrier. We hypothesize that sustained
release of NAGase for biofilm degradation can reduce the formation of biofilms and
increase the effectiveness of antibiotics to aid in reducing CRBSIs.
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I.

INTRODUCTION

A. Objectives and Specific Aims
Catheter related blood stream infections (CRBSIs) result in significant mortality
and morbidity in critically ill patients. The Center for Disease Control and Prevention
(CDC) has stated that there are approximately 250,000 cases per year (O'Grady M.D., et
al., 2002). The precise economic impact is difficult to quantify and estimates have varied
from $4,888 to $56,167 per patient in studies performed over the past decade (Goede
M.D. & Coopersmith M.D., 2009). The infections form when catheters become colonized
by organisms from the skin, the environment or the bloodstream. They are often difficult
to treat because the disease causing organisms embed themselves in a protective layer,
called a biofilm, on the surface of the catheter that results in an increased resistance to
antimicrobial agents (Dwyer, 2008). Therefore, in order to overcome the biofilm, a novel
nanoparticle composed of chitosan encapsulating a biofilm degrading enzyme, β-Nacetylglucosaminidase (NAGase) (Li & Li, 1970) was developed. It is the hope that this
therapy could help to reduce the number of CRBSIs per a year, the cost associated with
the illness and provide long term protection against the risk of CRBSIs.
In order for the nanoparticles to become an effective therapy several specific aims
must be met. First, the nanoparticles must be characterized and optimized for the
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application. This includes their size, zeta potential and morphological characterization.
Second, the nanoparticles must exhibit pH-dependent swelling properties; in order, to
provide the needed burst release followed by sustained release. Finally, the actual release
kinetics of the NAGase from the chitosan nanoparticles must be optimized.

B. Catheter Related Blood Stream Infections (CRBSIs)
Catheters represent an essential part of management of critically ill and
chronically ill patients. However, their use is often complicated by serious infections,
namely catheter related blood stream infections (CRBSIs), which are associated with
increased morbidity, hospital stay and medical costs (Dwyer, 2008). Risk factors for
CRBSIs include: reason for catheter use, length of catheter implantation, patient location
(outpatient, inpatient floor, ICU), type of catheter, number of manipulations per a day,
presence of needless connectors (increases risk), placement and whether or not best
practices are followed (Goede M.D. & Coopersmith M.D., 2009).
Current therapies, besides prevention practices; include, microbial impregnated
catheters and dressings, silver impregnated catheters, aseptic catheter hubs and
antimicrobial/anticoagulant flush solutions (Raad, Costerton, Sabharwal, Sacilowski,
Anaissie, & Bodey, 1993) (Goede M.D. & Coopersmith M.D., 2009). The first therapy is
the use of a sponge impregnated with chlorhexidine gluconate, which is applied at the
catheter insertion site. It has been shown to reduce skin colonization and bacterial
migration along the external surface of the catheter as compared with just skin
disinfection techniques, but only for a few days. Also, there have been reports of local
dermatitis. Another technique is the use of a silver impregnated collagen cuff attached to
the catheter and left below the skin catheter insertion site. However, the clinical data as to
5

its efficacy is conflicting and it was shown to make no difference after 20 days. The 20
day limit was thought to be due to either the collagen degrading or all the silver ions
being released within 3-7 days. Lastly, this technique requires an experienced physician
for insertion; in order, to limit the protrusion of cuff after insertion (Cicalini, Palmieri, &
Petrosillo, 2004). Other heavily researched therapies; include, catheters impregnated with
antimicrobial agents. The first best studied impregnated catheter is one coated with
chlorhexidine and silver sulfadiazine. It has been proven to decrease the risk for
colonization by at least four fold as compared to non-coated catheters. The main
limitation is the poor efficacy documented for long tern use (greater than 2 weeks).
Logghe, accounted this to be due to the reduced activities of the antiseptics and lack of
protection against external contamination (Logghe, Van Ossel, D'Hoore, Ezzedine,
Wauters, & Haxhe, 1997). As of now, no resistances to the antiseptic components have
yet been documented; however, there have been reports of allergic reactions. The second
well studied impregnated catheter is coated with minocycline-rifampin. This coated
catheter has been shown to have a lower rate of infection than the chlorhexidine/silver
sulfadiazine coated catheters. Also this type of coated catheter has been shown to retain
antibiotic activity for greater than 2 weeks (Marciante, Veenstra, Lipsky, & Saint, 2003).
Currently, there have been no documented cases of antimicrobial resistances to this type
of catheter in-vivo but there have been reports in in-vitro studies. It was suggested that
this could be due to antibiotics being repeatedly exposed to the in-vitro bacteria without
maintaining minimal therapeutic antibiotic use; therefore, the bacteria might be gaining
mechanisms for antibiotic resistance (Cicalini, Palmieri, & Petrosillo, 2004). Silver
impregnated catheters are also widely used but a recently published study of a
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combination of other studies showed no evidence that it reduces catheter colonization
(Goede M.D. & Coopersmith M.D., 2009). Another possible therapy is a catheter hub
containing iodinated alcohol solutions; however, this is only for internal catheter
protection (Cicalini, Palmieri, & Petrosillo, 2004). Finally, antimicrobial lock solutions
have been explored. In this technique an antimicrobial solution, often containing an
anticoagulant, is instilled in the lumen of the catheter and allowed to remain for 6-12
hours before it is removed. But due to the associated risk factors of the anticoagulants, it
is not recommended for routine use (Raad & Hanna, 2002).
Several therapies have been shown to significantly decrease the risk of CRBSIs;
however, most have only worked for the short term, less than 10 days (Karchmer, 2009).
There are several reasons for this including but not limited to: all antimicrobial agents
being released within the first few days, degradation or failure of the antimicrobial
delivery system, repeated exposure to antibiotics resulting in antibiotic resistance and
external contamination. Therefore, it is imperative to develop a safe and effective therapy
against CRBSIs for long term catheter use in patients

C. Biofilms
The common bacteria involved in catheter related infections are S. epidermidis, S.
aureus, Candida albicans, Pseudomonas aeruginosa, Klebsiella pneumoniae, and
Enterococcus faecalis (Raad and Hanna 2001, Donlan 2001). These bacteria aggregate
and anchor to catheter surfaces and form biofilms through substances they secrete. The
biofilm then acts as a protective matrix with its growth correlating to antibiotic resistance,
one of the main causes of failure for short and long term catheter failure (Dwyer, 2008).
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Biofilms are not necessary for bacteria to adhere to catheters, but they are
essential for bacteria to colonize on the catheter surface. The biofilms are composed of
water (up to 97%), polysaccharides (1-2%) and proteins (< 1%), in which bacteria (2-5%)
encase themselves (Sutherland, 2001). They have channels and fluid filled voids that are
approximately 1 µm or less (Drury, Stewart, & Characklis, 1993). These channels and
voids are used to facilitate the flow of nutrients, enzymes, metabolites, waste products
and other solutes (Sutherland, 2001). They can also lead to local accumulation of waste
products due to differences in colony density, which can create microenvironments of
differing pH (Stewart & Costerton, 2001). This creates an architecture that is both
heterogeneous and structurally complex. However, it is this architecture that will be
exploited for the design of the chitosan nanoparticles. The first exploitation will be the
chitosan nanoparticles small size, which will allow for easier entry into the small
channels and voids. Secondly, the low pH microenvironments are also important; in
order, for the pH-dependent chitosan nanoparticles to provide a burst release of the
encapsulated biofilm degrading enzyme, NAGase.
As mentioned previously, biofilm degradation is important to this application
since both early and late catheter failure is due to its growth being correlated to antibiotic
resistance. The antibiotic resistance is thought to be achieved through three main
mechanisms. The first is the slow or incomplete penetration of the drug due to the ability
of the biofilm to act as a protective layer (Stewart & Costerton, 2001). The second is the
possibility of a bacterial subpopulation differentiating into a unique phenotype that
protects it from the effects of antibiotics (Sutherland, 2001). And third, is the local
microenvironments mentioned previously, that have a low pH due to the bacteria’s
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metabolism. These local pH gradient microenvironments can deactivate the antibiotic or
causes the bacteria to enter a non-growing phase. These three mechanisms help the
bacteria evade immune responses and antimicrobial therapy; however, when the biofilm
is degraded the microorganisms rapidly become susceptible to the antibiotics, since all
protection from the biofilm is lost (Stewart & Costerton, 2001).

D. Biofilm Degradation
Biofilm degradation is essential; in order, to deliver therapeutic antibiotics that
will not be inhibited. To degrade biofilms, chitosan nanoparticles will act as a drug
delivery vehicle for the biofilm degrading enzyme β-N-acetylglucosaminidase (NAGase).
NAGase is a common enzyme found in almost all tissues and organs. It has a molecular
weight of 100 kDa and its optimal pH range for enzymatic activity is 3.5 to 6 (Li & Li,
1970). This enzymatic range is especially important, since the NAGase activity is only
wanted and required at the lower pH ranges of the biofilm microenvironments. It is also
important to note that NAGase can degrade the terminal ends of chitosan. But since it has
minimal activity at higher pHs it should not affect the drug delivery vehicle until it
reaches the low pH microenvironments of the biofilm. Once targeted the terminal
degradation could be beneficial for a better burst release of the NAGase.
The main reason for using NAGase is its ability to hydrolyze β-Nacetylglucosaminyl linkages found in amino-sugar containing compounds such as
glycoproteins, glycolipids, blood group substances and bacterial cell walls (Li & Li,
1970). For example, Straphylococcus epidermidis as mentioned earlier represents one of
the most frequent causes of CRBSIs. It has a very well characterized polysaccharide,
within its biofilm, that consists of 80-85 % N-acetyl-D-glucosaminyl residues and 15-20
9

% non-N-acetylated positively charged n-glucosaminyl residues that are joined by the
same β-N-acetylglucosaminyl linkage (Figure 1) that can be degraded by NAGase (Mack,
et al., 1996)

Figure 1 - β-N-acetylglucosaminyl Linkage in Straphylococcus epidermidis
The ability of NAGase to degrade biofilms has also been proven in other CRBSIs
causing bacteria, such as Candida albicans (Al-fattani & Douglas, 2006). In conclusion,
the ability to degrade polysaccharides, one of the main components of biofilms, is
essential in its overall degradation.

E. Chitosan
Chitosan (Figure 2) is made of linear β(1→4)-linked glucosamine and N-acetyl
glucosamine units. It is obtained from deacetylation of chitin (Figure 3), a naturally
occurring polysaccharide found abundantly in murine crustaceans, such as crabs and
shrimp (Prabaharan & Mano, 2005). Due to its abundance, low production cost, and
intrinsic properties chitosan has become a choice material for medical and
pharmaceutical applications; such as, carriers for drugs, protein carriers and gels for the
entrapment of cells or antigens (Ko, Park, Hwang, Park, & Lee, 2002). However, this
introduction will only focus on chitosan nanoparticles as protein carriers.
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Figure 2: Chemical Structure of Chitosan

Figure 3 - Chemical Structure of Chitin
Chitosan has been receiving increased attention due to its intrinsic properties. The
first important intrinsic property is chitosan’s proven biocompatibility, which allows for
topical application, injection or implantation Secondly, it is metabolized by a human
lysosome, which makes it biodegradable (Berger, Reist, Mayer, Felt, Peppas, & Gurny,
2004). Thirdly and perhaps most importantly for this application is that chitosan exhibits
pH dependent swelling properties, which is essential to control the NAGase release (Gan,
Wang, Cochrane, & McCarron, 2005). Chitosan is also associated with a positive charge
at physiological pH, making it mucoadhesive. This helps increase retention at the site of
application, which again is important for this application; in order, to maintain controlled
drug release (Xu & Du, 2003). Finally, chitosan has been proven to promote wound
healing and has bateriostatic effects primarily through the inhibition of the transcription
of DNA (Liu, Guan, Yang, Li, & Yao, 2000). This bateriostatic effect could act as an
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additional inhibitor of biofilms making chitosan an even more attractive drug delivery
vehicle.
Currently, there are several procedures to create chitosan particles. These
techniques can be broken down into covalently or ionically cross-linked particles. The
earliest work in chitosan nanostructures predominantly involved chemical cross-linking
reactions to the polymer chain. Watzke and Dieschbourg (1994) formed chitosan-silica
nanocomposites by reacting tetramethoxysilane (TMOS) to hydroxyl groups on the
chitosan monomer. Later, Ohya (1994) and colleagues were the first to present data
involving chitosan nanospheres for drug delivery applications using a water-in-oil
emulsion method followed by cross-linking of the amino groups with glutaraldehyde.
Although, these pioneering studies demonstrated feasibility of synthesizing stable,
reproducible nanosized chitosan particles it was later discovered that the cross-linking
agent, glutaraldehyde, had negative effects on cell viability and the integrity of
macromolecular drugs. Therefore, general interest shifted to less harsh procedures for the
synthesis of chitosan particles.
The shift was made to ionically cross-linked particles that exploited the cationic
nature of chitosan and its ability to gel on contact with specific polyanions. Bodmeier
(1989), first reported ionotropic gelation of chitosan with tripolyphosphate (TPP) for drug
encapsulation to create microspheres. Calvo (1997) and colleagues later refined the
method for nanoparticle (200-1000 nm) fabrication by the addition of an alkaline phase
(pH 7-9) containing TPP with into an acidic phase (pH 5-6) containing chitosan (Figure
4).
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Figure 4 - Ionic Gelation for Formation of Chitosan Particles
For this method the nanoparticles form instantaneously upon mixing of the two solutions
through inter and intramolecular linkages created between TPP phosphates and chitosan
amino groups. This method presents several attractive features for a drug delivery vehicle
because the process is simple and mild, meaning the fabrication process is easier and
should not cause any inactivity or structural changes to the enzyme NAGase. Also the
nanoparticle solution created is very homogenous and contains nanoparticles whose size
and charge can easily be adjusted via concentration of TPP and chitosan; as well as,
chitosan molecular weight and chitosan deacetylation degree (Calvo, Remunan, J.L.V., &
Alonso, 1997). Lastly, in addition to Calvo, there are several other published studies
confirming the large capacity load for proteins in chitosan-TPP particles reference.

F. Design Overview
Due to the attractive features of the ionotropic gelation method for chitosan
nanoparticles, it was used in the following studies as a possible protein carrier for
NAGase. It is important to note that formation of nanoparticles via this method depends
upon the purity of the chitosan, the acid needed for dissolution of the chitosan, and the
molecular weight of the chitosan. Consequently, these conditions are different for every
individual chitosan type; therefore, nanoparticles for this application will need to be
optimized due to a difference in chitosan source from other published studies. It is also
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imperative that these particles be optimized for a size less than 1 µm (Drury, Stewart, &
Characklis, 1993); in order, for the nanoparticles to diffuse easily into the biofilm. These
nanoparticles must also exhibit swelling and degradation in a pH 5 environment, so that
the enzyme NAGase will be released and active. Finally, burst release followed by
sustained release of the NAGase must be shown for a continued therapeutic effect.
Therefore, the following studies are focused on optimizing size, zeta-potential,
morphological characteristics, swelling properties, encapsulation efficiencies and release
profiles of chitosan-TPP nanoparticles for use as biofilm degrading enzyme carrier.
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II.

PROCEDURE

Chitosan particles encapsulating NAGase were fabricated to degrade biofilms; in
order, to overcome antibiotic resistant barriers in CRBSIs. The following sections
represent procedures to fabricate the chitosan particles encapsulating NAGase; as well as,
procedures to characterize, optimize and prove their efficacy for this particular
application. It will be important to prove that the chitosan particles are nano-sized in to fit
within the fluid filled microchannels of the biofilm; in order, to deliver the NAGase to an
effective site. This was achieved through digital light microscopy and scanning electron
microscopy. The zeta potential was also found to confirm the mucoadhesive properties of
the chitosan and to confirm the chemistry of ionic gelation. The best separation procedure
of chitosan particles was also determined so that they could be used in additional studies.
Within the separation procedures the poor mechanical properties of chitosan particles was
confirmed; therefore, additional studies with crosslinkers to improve mechanical strength
was completed. It was also important to show is that the chitosan particles exhibited pH
dependent swelling properties so that the NAGase can be released and active in the low
pH biofilm microenvironments. Finally, the encapsulation and release of NAGase from
the chitosan particles must be shown to prove the validity of the concept. It is also
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important to note that for some encapsulation and release studies BSA was used as a
model protein for cost effectiveness reasons.

A. Fabrication of Chitosan Particles
The chitosan particles were obtained through ionic gelation of chitosan (CS) with
tripolyphosphate (TPP). Preliminary experiments were conducted to discover the optimal
production zone needed for CS particle formation, which should be less than 1 µm, with
200-400 nm being the desired CS particle size. The 1 µm limit is based on the max size
of the fluid filled channels in biofilms (Drury, Stewart, & Characklis, 1993); therefore, if
CS particles are larger they cannot diffuse into the biofilm for a more targeted NAGase
release. The nano-sized CS particles were found by varying the molecular weight and
deacetylation of chitosan; as well as, the concentration of the chitosan and TPP solution.
The molecular weight is an important optimization parameter because higher molecular
weights (>400 kDa) often cause the CS solution to be too viscous; therefore, causing CS
to clump rather than form CS particles. However, if the chitosan molecular weight is too
low (<100 kDa) than the encapsulation efficiencies of the drug of interest is too low.
These properties were expected and are related to linear chain length of the chitosan.
Deacetylation, the removal of an acetyl group, is important so that the amino group is
exposed. It is critical this group be exposed since ionic gelation depends on the positive
charge of the amino group and the negative groups of the TPP. Therefore, the higher
deacetylation percentages allow for more crosslinking to occur in the ionic gelation
procedure.
These experiments were completed with both low and high molecular weight
chitosan. The low (LMW) and high (HMW) molecular weight chitosan was purchased
16

from Sigma Aldrich (St. Louis, MI), which was 91.8 % and 75.6 % deactylated with a
viscosity of 32 cps and 1406 cps. In later experiments, chitosan produced within a
narrower deacetylation percentage and molecular weight was obtained from Heppe
Medical Chitosan (Germany). The chitosan was approximately 90 % deactylated with
three different molecular weights of 150, 250 and 350 kDa (Table I). This switch of
chitosan manufacturers was critical to produce CS particles that were of constant size and
low polydispersity; in order, to increase reproducibility.
TABLE I
CHITOSAN HEPPE MEDICAL CHITOSAN SOURCE INFORMATION
1
2
3
Molecular Weight
150
250
350
Viscosity (cps)
36
250
680
Deacetylation %
92.1
88.1
88.7

It is also important to note that the exact molecular weight of chitosan was not known for
the Sigma Aldrich chitosan, as only the viscosities were reported. The method for CS
particle fabrication, no matter the type of chitosan used, is shown below in Figure 5.
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% CS Solution: Dissolve in D.I. water with an acetic acid
concentration 1.75 times that of the CS concentration

% TPP Solution: Dissolve in D.I. water. Might
need to adjust pH using HCL or NaOH.
% CS Solution: Dissolve in D.I. water with an acetic acid
concentration 1.75 times that of the CS concentration

CS Particles: Sonicate TPP and CS
solution at a ratio of (1:3.5).
Sonicate at 5 W at 25 °C
Figure 5 - Ionic Gelation Method for Chitosan Particle Formation
1. Low Molecular Weight Chitosan Particles
For LMW chitosan, CS was dissolved in 99.7+ % acetic acid (Sigma Aldrich St.
Louis, MI) aqueous solution at various CS concentrations: 0.125%, 0.25 %, 0.5 %, 1%,
and 2 % (w/v). The concentration of acetic acid was 1.75 times higher than that of CS in
all cases, which resulted in a solution pH of approximately 3.5. Next, TPP (Sigma
Aldrich, St. Louis, MI) was dissolved in deionized (D.I.) water at the same concentrations
as CS (0.125%, 0.25 %, 0.5 %, 1%, and 2 % (w/v)). Lastly, the TPP solution was slowly
pipetted into the CS solution for a 1:3.5 (TPP:CS) ratio while being sonicated (Microson
XL 2000, Misonix, Farmingdale, NY) at 5 Watts (W) at room temperature (25 °C). Some
studies which will be noted later adjusted the pH of the TPP solution to 4.5 using various
concentrations of hydrochloric acid (Fisher Scientific, Fair Lawn, NJ) or sodium
hydroxide (Fisher Scientific, Fair Lawn, NJ).
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2. High Molecular Weight Chitosan Particles
For HMW chitosan, only 0.25 and 0.5 % (w/v) concentrations of CS solutions
were used. The concentration of acetic acid remained 1.75 times that of the CS %
concentration. The concentrations of TPP solutions were 1.5 %, 2 % and 2.5 % (w/v) and
the pH of the solutions were adjusted to pH 4.5 every time, using sodium hydroxide and
hydrochloric acid. The changes in percentages of CS solution were needed so that the
solution was not too viscous for particle formation. The change in TPP solution was also
made based on the assumption there would be more amino groups that needed to be
crosslinked for CS particle formation. Lastly, the TPP solution was slowly pippeted to the
CS solution at a 1:3.5 (TPP:CS) ratio while being sonicated at 5 W at room temperature
(25 °C).
3. Heppe Medical Chitosan Particles
To find the optimal production zone for Heppe Medical Chitosan particles, three
factors were varied; including: molecular weight of chitosan (150, 250 & 350 kDa),
chitosan % concentrations (0.125, 0.25, 0.5 and 1 %) and TPP % concentrations (1, 2.5,
5, 10 and 15 mg/mL). The CS particles were then created using the same procedure as
described for HMW chitosan. It is important to note that the acetic acid concentration,
and ratio of CS added to TPP remained the same, 1:3.5 (TPP:CS).

B. Size and Zeta Potential Measurement of Chitosan Particles
Size and zeta-potential measurements of the CS particles were performed using a
Zetasizer Nano ZS90 (Malvern Instruments, England). Size and zeta potential
measurements were taken for the different types of chitosan used to fabricate CS particles
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as described in the procedure above. Size measurements were also used several times as a
critical analysis tool for other studies as described in other sections.
To determine size (diameter), dynamic light scattering capabilities of the
ZetaSizer Nano ZS90 were exploited. To use, 1 mL of CS particles was pipetted into a
low volume disposable sizing cuvette “ZEN0112” (Malvern Instruments, England) and
placed at a 90° angle to the detector. The measurement was taken with a preprogrammed
standard operating protocol (SOP) file. To program the file, start a manual measurement
and set the following parameters.


Material: Polystyrene latex
o R.I.: 1.590
o Absorption: 0.01



Dispersant: Water (Note: Acetic acid concentration so low does not affect
measurement value)
o Temperature: 25 °C
o Viscosity: .8872 cps
o R.I. 1.330
To find zeta potential, 1 mL of CS particles is pipetted into the clear disposable

zeta cell cuvette (Malvern Instruments, England). The measurement was taken with a
different preprogrammed standard operating protocol (SOP) file. To program the file,
start a manual measurement and set the following parameters.


Material: Chitosan
o R.I.: 1.528
o Absorption: 0.00
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Dispersant: Water (Note: Acetic acid concentration so low does not affect
measurement value)
o Temperature: 25 °C
o Viscosity: .8872 cps
o R.I. 1.330

Cuvette can be reused up to ten times. Before each reuse rinse with D.I. Water, Ethanol
(Pharmco, Brookfield, CT), D.I. Water and then dry with an air hose.

C. Determination of Chitosan Particle Separation Method
Several methods were investigated to determine the best method for CS particle
separation. This was essential; in order, for CS particles to be used in additional studies
were the CS particles needed to be transferred to different buffers i.e. swelling studies. It
is also important to note that the method of separation was difficult due to the poor
mechanical properties of the CS particles and their fabrication efficiencies. Methods
investigated; included rotary evaporation and high speed centrifugation.
1. Low Molecular Weight Chitosan Particles
For these methods, CS particles composed of 0.5 % TPP and 0.5 % LMW CS
solutions were fabricated and their size measured as described in sections A and B (§A &
§B). For rotary evaporation, the sample was dialyzed against D.I. water (Spectra/Por
Dialysis Membrane MWCO: 6-8,000 kDa; Rancho Dominguez, CA) for 24 hours. The
CS particle solution was then transferred to a rotavap (Buchi, New Castle, DE) until the
water solution was completely evaporated, leaving only the CS particles. These CS
particles were then resuspended in 1 mL D.I. water and their size measured for
comparison (§B). The second method involved high speed centrifugation (Sorvall RC6,
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Kendro, Asheville, NC). The CS particle sizes were first measured (§B), then 1 mL of the
CS particle solution was transferred to a 1.5 mL microcentrifuge tube and centrifuged at
different time intervals (15 & 30 minutes) and speeds (1950, 8230, 12860, 18510, 28930,
39830 & 51430 x g’s). The temperature was always kept at 10° C. Some CS particle
samples were prepared with the addition of 20 µL of glycerin (Fisher Scientific, Fair
Lawn, NJ) before CS particles were added. After centrifugation, the supernatant was
removed and measured (§B). The CS particles were then resuspended in 1 mL D.I. water.
Finally, the CS particle sizes were again measured (§B). The experiment was repeated
when 0.5 mM genipin was added as a crosslinker and the TPP solution pH was adjusted
to 4.5. However, within the second study no glycerin was added and the time intervals
were changed (30 and 60 minutes), while the speeds were also changed (10,000, 20,000,
40,000 x g’s). It is important to note for all subsequent LMW CS studies the CS particles
will be centrifuged at 40,000 x g’s for 30 minutes at 10 °C unless otherwise noted. Figure
6 shows the procedural steps for this and all subsequent centrifugation studies.
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Measure CS particles size (§B)

Split CS particle solution into 1 mL samples
transferred to microcentrifuge tubes.

Centrifuge at various times and speeds.
Temperature always remains at 10 °C.

Remove supernatant with
pipette. Resuspend in 1 mL D.I.
Water. Measure size (§B)
Figure 6 - Chitosan Particle Separation by Centrifugation
2. Heppe Medical Chitosan Particles
For the Heppe Medical Chitosan, 1 mL CS particles composed of 0.1 % TPP at
pH 4.5 and 0.125 % CS250 were fabricated as described in section A (§A) and then
transferred to 1.5 mM microcentrifuge tubes. The CS particle sizes were measured before
centrifugation (§B). Next, the CS particles were centrifuged at different time intervals (5,
30 and 60 minutes) and speeds (12860, 18510, 28930, 39830 x g’s). The temperature
remained at 10° C. After centrifugation, the supernatant was removed and measured (§B).
The CS particles were then resuspended in 1 mL D.I. water. Finally, the CS particle sizes
were again measured (§B). For all subsequent studies involving Heppe Medical CS
particles centrifugation will be performed at 39,830 x g’s for 60 minutes at 10 °C.

D. Determination of Crosslinker Methods for Chitosan Particles
In addition to TPP, three additional non-toxic crosslinkers were explored to
increase mechanical strength of the CS particles; including, sodium citrate (Fisher
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Scientific, Fair Lawn, NJ), genipin (Wako, Richmond, VA) and 3glycidoxypropyltrimethoxysilane “GPTMS” (Sigma Aldrich, St. Louis, MI). To analyze
the crosslinkers effects, a centrifugation size study and swelling study were performed.
Meaning, the size before centrifugation was measured (§B). The CS particles were
centrifuged as described in section C (§C). Next, after centrifugation, the supernatant was
removed and the CS particles were resuspended in 1 mL D.I. water, phosphate buffered
saline “PBS” (pH 7) (Fisher Scientific, Fair Lawn, NJ), sodium citrate buffer (pH 5) and
PBS (pH 2). The sizes at hour 0 and 24 were then measured (§B). The size data collected
at hour 0 of CS particles resuspended in D.I. water was also used for the after
centrifugation data. It is important to note that all studies were carried out using a 0.5 %
TPP with no pH adjustments and a 0.5 % LMW chitosan solution.
1. Trisodium Citrate Crosslinker
For sodium citrate, the CS particles were fabricated in a procedure similar to that
described in section A (§A). A solution containing 0.5 % (w/v) sodium citrate and 0.5 %
TPP was mixed. The 0.5% TPP/sodium citrate solution was slowly pipette, during
sonication, into the 0.5 % LMW CS solution at the same 1:3.5 (TPP/SodiumCitrate:CS)
ratio. The process steps are described in Figure 7.
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% LMW CS Solution: Dissolve in D.I. water with
an acetic acid concentration 1.75 times that of the
CS concentration

% Sodium Citrate/TPP Solution: Dissolve sodium citrate
and TPP at a 0.5 % (w/v) concentration in D.I. water. Mix
% CS Solution: Dissolve in D.I. water with an acetic acid
concentration 1.75 times that of the CS concentration

CS Particles: Sonicate Sodium Citrate/TPP
and CS solution at a ratio of (1:3.5).
Sonicate at 5 W at 25 °C
Figure 7 - Sodium Citrate Crosslinker Method for Chitosan Particles
2. GPTMS Crosslinker
The GPTMS crosslinker is added in two different methods. For the first method, a
solution containing 0.5 % (v/v) GPTMS and 0.5 % TPP was mixed. The 0.5 %
TPP/GPTMS solution was slowly pipetted, during sonication, into the 0.5 % LMW CS at
the same 1:3.5 (TPP/GPTMS:CS) ratio during sonication. The resulting solution was
continuously mixed on a magnetic stir plate (Barnstead International, Dubuque, IW) for
24 hours. For the second method, GPTMS was added to D.I. water for a final
concentration 0.5 % (v/v). Then equal volumes were mixed with previously fabricated CS
particles composed of 0.5 % TPP and 0.5 % LMW CS (1:3.5) solutions on a magnetic
stir plate for 24 hours. See Figure 8 for process steps.
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0.5 % LMW CS Solution: Dissolve in D.I. water
with an acetic acid concentration 1.75 times that of
the CS concentration

Method 1: Dissolve GPTMS
(v/v) and TPP (w/v) at a 0.5 %
concentration in D.I. water. Mix

Method 2: Dissolve TPP at a
0.5 % (w/v) concentration in
D.I. water. Mix
water. Mix

CS Particles: Sonicate solutions
a
% CSatSolution:
Dissolve in D.I. water with an acetic acid
1:3.5 (TPP/GPTMS:CS) ratio
concentration 1.75 times that of the CS concentration
Sonicate at 5 W at 25 °C
Method 2: Dissolve GPTMS in D.I. Water at
a 0.5 % (v/v) concentration. Add to CS particle
solution at a 1:3.5 (GPMTS:TPP/CS) ratio and
mix for 24 hours.
Figure 8 - GPTMS Crosslinker Method for Chitosan Particles
3. Genipin Crosslinker
Genipin is insoluble in water; therefore, 1.13 mg of genipin was added to 1 mL of
ethanol. After dissolution, the solution was transferred to 9 mL D.I. water for a final
genipin concentration of 0.5 mM. For the first method no TPP was added. Instead, the 0.5
mM genipin solution was added to the 0.5 % CS solution at a ratio of 1:3.5 (genipin:CS)
and continuously stirred for 24 hours. The second method added the 0.5 mM genipin
solution to the 0.5 % TPP solution at a ratio of 1:1 (genipin:TPP). The genipin/TPP
solution is then mixed with the 0.5 % LMW CS solution at a ratio 1:3.5
(TPP/genipin:CS) and continuously stirred for 24 hours. The third method added the 0.5
mM genipin solution after 0.5 % TPP and 0.5 % LMW CS (1:3.5) particle formation at
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the same ratio of TPP added. The solution was continuously stirred for 24 hours. It is
important to note that this study was repeated twice; however, the pH of the 0.5 % TPP
solution was lowered to pH 4.5 using sodium hydroxide. See Figure 9 for process steps.

0.5 % LMW CS Solution: Dissolve in D.I. water with an acetic
acid concentration 1.75 times that of the CS concentration

Genipin Solution: Dissolved
in ethanol and then added to
D.I. water for a .5 mM
concentration

Method 1: 0.5 mM
genipin solution only.

Method 2: Dissolve
.5 mM genipin (v/v)
and 0.5 % TPP (w/v)
at a 1:1 ratio. Mix

Method 3: Dissolve
TPP at a 0.5 % (w/v)
concentration in D.I.
water. Mix

CS Particles: Sonicate solutions at a
1:3.5 (TPP/Genipin:CS) ratio

Method 3: Add 0.5 mM genipin solution to
CS particle solution at a 1:3.5
(Genipin:TPP/CS) ratio and mix for 24 hours.
Figure 9 - Genipin Crosslinker Method for LMW Chitosan Particles
4. Heppe Medical Chitosan Genipin Crosslinker
For the Heppe Medical Chitosan, the size difference crosslinked with a 1 mM
genipin solution was also determined. It is important to note that a concentrated genipin
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solution was created for direct addition to the CS particle solution; instead of first being
diluted in water. The genipin solution was created by dissolving 1 g genipin in 5 mL of
ethanol. From there the genipin solution was added to 7 mL of a CS particle solution
composed of 0.1 % TPP pH 4.5 and 0.125 % CS (§A), for a final genipin concentration
of 1 mM. The concentration of genipin was increased from .5 mM in previous studies to
1 mM to determine if it caused a more dramatic effect on size of the CS particles both
before and after centrifugation (§C). The resulting solution was continuously stirred for
24 hours on a rotating shaker. See Figure 10 for process steps.
0.125 % Heppe Medical CS Solution: Dissolve in
D.I. water with an acetic acid concentration 1.75
times that of the CS concentration

Method 2: Dissolve TPP at a
0.5 % (w/v) concentration in
D.I. water. Mix
water. Mix
% CS Solution: Dissolve in D.I. water with an acetic acid

CS Particles:
Sonicate
solutions
concentration
1.75 times
that of the CS concentration
at a 1:3.5 (TPP/:CS) ratio
Sonicate at 5 W at 25 °C

Genipin dissolved in
ethanol at a 20 % (w/v)
concentration

Add genipin solution to CS particle
solution for a 1 mM concentration

Figure 10 - Genipin Crosslinker Method for Heppe Medical Chitosan Particles
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E. Morphological Characterization of Chitosan Particles
1. Low Molecular Weight Chitosan Particles
Morphological features were examined via scanning electron microscopy (SEM:
Evo 40, Zeiss, Germany). Different CS particle solution composed of either 0.25, 0.5 or
1% TPP and 0.25, 0.5 or 1 % LMW CS were used for this morphological characterization
study. For preparations of samples, a droplet of homogenous CS particle solution was
prepared on a copper grid having a mesh of 300 (Election Microscopy Sciences, Hatfield,
PA). The CS particles were then allowed to air dry at room temperature for 24 hours. All
samples were then coated with gold palladium, at a thickness of approximately 100 Å for
SEM (FEI Nova NanoSEM, Hillsboro, OR) observation. It is important to note that all
images were taken at a low voltage of 2 kV, due to the charging effects causing the
samples to bleach out. The CS particle size distribution and morphology were then
analyzed using Image J (NIH).
2. Heppe Medical Chitosan Particles
SEM pictures of the Heppe Medical Chitosan particles, composed of 0.1 % TPP
pH 4.5 and 0.125 % CS250, were taken. A droplet of homogenous CS particle solution,
was prepared on a copper grid. The CS particles then adhered to the surface for 5 minutes
before some of the CS particle suspension liquid was removed via fluid absorption with a
kimwipe. The CS particles were then allowed to air dry for 24 hours. All preparations
were then coated with gold palladium at a thickness of approximately 100 Å for SEM
observation. Pictures were taken at 6 kV, using a different SEM to determine if imaging
difficulties were due to instrumentation.
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F. Different pH TPP Solutions Effect on Chitosan Particle Size
The following study was created to determine the size effects of a TPP solution
with a varying pH. This was done based on previous literature that states when the pH of
the TPP solution is lowered, the diameter of the CS particles decreases (Gan, Wang,
Cochrane, & McCarron, 2005). A 0.5 % TPP solution was created and its pH adjusted to
4, 4.5 or 5 using sodium hydroxide or hydrochloric acid. CS particles where than
fabricated with a 0.5 % LMW CS as described in section A (§A). The 0.5 % TPP solution
was sonicated with the 0.5 % LMW CS solution at a 1:3.5 (TPP:CS) ratio. The diameter
of the subsequent CS particles was measured (§B). For the Heppe Medical Chitosan, the
size difference for TPP solutions at pH 4.5 and 9 was also determined.

G. Swelling Effect on Chitosan Particles in Various pH
1. Low Molecular Weight Chitosan Particles
CS particles composed of 0.5 % TPP and 0.5 % LMW CS were created in a large
batch by maintaining the same ratios of CS to TPP as described in the CS particle
preparation section (§A). 1 mL aliquots where transferred to 1.5 mL microcentrifuge
tubes and separated using high speed centrifugation as per section C (§C). The
supernatant was discarded and the aliquots were resuspended in either D.I. water, PBS
(pH 7), sodium citrate buffer (pH 5) or PBS (pH 2). The CS particle sizes were measured
at t = 0, 2, 4, 8, 24, 48, 96, 168, 336 and 672 hours using the same procedure as described
in a section B (§B). In between time points the samples were stored in an incubator (VWI
International, West Chester, PA) set at 37 °C.
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2. pH Back Titration Study
A pH back titration study was completed because in previous swelling studies CS
particles swelled in both PBS (pH 7) and sodium citrate buffer (pH 5); therefore, it was
important to determine if the reaction was reversible or if there was a point when no
swelling occurred. In this study, CS particles where fabricated from 0.1 % TPP pH 4.5
and 0.125 % CS250 solution as described in section A (§A). The CS particles where
centrifuged (§C). The supernatant was then discarded and replaced with PBS (pH 7), PBS
(pH8) or sodium citrate buffer (pH 5). Their size was measured at hour 0 (§B). For the
resuspended CS particles in PBS (pH 7) the pH of their buffer was adjusted to pH 5 with
either .01 N HCL or sodium citrate buffer. For the other resuspended CS particles in PBS
(pH 7), the pH of their buffer was adjusted to pH 8 with either .01 NaOH or PBS (pH 8).
The pH was constantly measured using a pH meter (Denver Instruments, Germany).
Finally, after the pH adjustments the sizes were again measured (§B).

H. BSA Encapsulation in Chitosan Particles
To study and optimize the encapsulation of a drug in the CS particles, bovine
serum albumin “BSA” (Equitech Bio Inc., Kerrville, TN) was used as a model drug. BSA
was used based on its cost effectiveness. BSA was dissolved directly into the 0.5 %
LMW CS solution at concentrations of 0.25, 0.5, 1 and 2 mg/mL BSA. CS particles were
then fabricated as described in section A (§A). It is important to note that the 0.5 % TPP
solution was adjusted to pH 4.5. The crosslinker genipin was also added after CS particle
fabrication at a 0.5 mM concentration. For comparison CS particles without BSA were
fabricated. The CS particles were separated by centrifugation (§C). 100 uL of the
supernatant was pipetted into microcuvettes and measured at a wavelength of 280 nm by
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spectrophotometer (Beckman Coulter Du 530, Brea, CA), to determine the encapsulation
efficiency. BSA concentrations were determined from a standard curve of known BSA
concentrations versus absorption. To calculate encapsulation efficiency the following
equation (Equation 1) was used.

Encapsulation Efficiency =

Total Amt. BSA − Free Amt. BSA
∗ 100 (Equation 1)
Total Amt. BSA

BSA concentration was also measured using a bicinchoninic “BCA” assay (Sigma
Aldrich, St. Louis, MI) to calculate BSA encapsulation efficiency. The same
encapsulation efficiency protocol was followed; however, 150 µL of the supernatant was
transferred to a 96 well plate. The assay protocol was completed as recommended by the
vendor. It is important to note that the assay works by correlating protein concentration to
a colormetric change produced by BCA binding to Cu1+ under alkaline conditions. Cu1+ is
produced by reduction of Cu2+ by cysteine, cystine, tryptophan, tyrosine and peptide
bonds of the protein of interest. The 96 well plated was placed in an incubator for 2 hours
at 37 °C before measuring the absorbance at 562 nm with a plate reader (BioTek
ELX800, Winooski, VT).
Encapsulation was also visualized using confocal microscopy. Fluorescent
microscopy was not used because the resolution was too low to see CS particles properly.
In order, to view CS particles via confocal microscopy they were encapsulated with BSA
conjugated to fluorescein isothiocyanate “FITC” (Invitrogen, Eugene, OR). To use the
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BSA conjugated to FITC, 5 mg BSA+FITC was dissolved in 2 mL D.I. water. HMW CS
particles were then fabricated using 0.5 % TPP pH 4.5 and 0.5 % HMW CS solutions,
which were then crosslinked with 0.5 mM genipin. It is important to note that the BSA
was encapsulated by two different methods. The first method involved mixing the 0.125
mg/mL BSA+FITC with the CS solution before adding the TPP or genipin. The second
method involved allowing the 0.125 mg/mL BSA+FITC to diffuse into the CS particles
after fabrication. After the CS particles were fabricated they were allowed to dry on a
glass cover slip overnight. The CS particles were also imagined when wet. Imagines were
captured during a Zeiss confocal microscopy demonstration.

I. BSA Release from CS Particles
1. Low Molecular Weight Chitosan Particles
Before BSA release studies were completed, swelling studies of CS particles
encapsulating BSA was completed. This was done to help better explain the release
kinetics of BSA during release studies. 0.125 mg/mL BSA was encapsulated into LMW
CS particles as described above for encapsulation efficiency studies (§G). For
comparison, CS particles without BSA were also made. Next, 1 mL samples from CS
particle solutions were centrifuged (§C). The supernatant was removed and replaced with
either PBS (pH 7) or sodium citrate buffer (pH 5). Lastly, their size was measured over
time at t= 0, 1 and 4 hours.
1 mg/mL BSA encapsulated particles were prepared as described above for
encapsulation efficiency studies (§G). After the initial 100 l of supernatant was removed
for encapsulation efficiency studies, the remainder was discarded and the CS particles
were resuspended in D.I. water, PBS (pH 7) or sodium citrate (pH 5). At t=0, 1, 2, 4 and
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8 hours, 100 µL of the samples were removed and its absorbance at 280 nm was
measured by spectrophotometer. For all suspensions, the blank was appropriately
matched to the suspension buffer. In between time points, the samples should be kept in
an incubator at 37 °C and agitated occasionally to prevent the CS particles from settling
on the bottom of the microcentrifuge tubes.
The sensitivity of the spectrophotometer is limited and cannot accurately measure
the low BSA release concentrations. Therefore, BSA conjugated to FITC was used;
instead, of just BSA. A fluorometer (Turner Biosystems, Sunnyvale, CA) was used to
measure the amount of BSA release. CS particles were fabricated from 0.5 % TPP pH 4.5
and 0.5 % CS solutions (§A), which were crosslinked with 1 mM genipin. A 100 µL of
the dissolved BSA-FITC solution was then added to 1 mL CS particle solution for a final
concentration of 0.25 mg/mL. The CS particles were then continuously mixed overnight
on a rotating plate. Next, the CS particles were separated by centrifugation (§C). 200 µL
of the supernatant was removed and measured with the fluorometer (460/515-570
wavelengths) to calculate the encapsulation efficiency. The remaining supernatant was
discarded and replaced with either PBS (pH 7) or sodium citrate buffer (pH 5).
Fluorometric readings of 200 l samples (which were replaced with the appropriate
buffer) were then taken at t= 0, 1, 2, 4 and 8 hours. In between time points sampled were
placed in an incubator at 37 °C. Measurements were compared to a standard curve of
known concentrations of BSA-FITC.
Release studies of BSA from particles were also performed to determine the effect
of continuous mixing. CS particles were created following the protocol described above.
50 µL of the BSA-FITC solution was added to a 1 mL aliquot of CS particles in 1.5 mL
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centrifuge tubes for a final BSA concentration 0.125 mg/mL. The CS particles were
continuously mixed on a rotating plate for 24 hours. The BSA concentration was lowered
from 0.25 to 0.125 mg/mL BSA-FITC based on over-saturation that was occurring in the
previous procedure. Next, the CS particles where centrifuged (§C). After centrifugation,
50 µL of the supernatant was diluted in 50 µL of D.I. water and measured using a
fluorometer. The rest of the supernatant was discarded and the CS particles were
resuspended in PBS (pH 7) or sodium citrate buffer (pH 5). The samples were then
transferred to a 48 well plate and mixed on a magnetic stir plate. At 0, 1, 2, 4 and 8 hours
100 µL samples (which were replaced with the appropriate buffer) were removed to be
measured using a fluorometer.
2. Heppe Medical Chitosan Particles
The swelling studies were again repeated for the Heppe Medical Chitosan. CS
particles were fabricated from 0.1 % TPP pH 4.5 and 0.125 % CS (250 kDa) solutions.
The BSA was encapsulated following two different methods. In the first method, 250 µL
BSA was added to the CS solution before CS particle formation. In the second method,
250 µL BSA was added after CS particle formation. Both resulted in a final BSA
concentration of .125 mg/mL. After formation, both types of BSA encapsulated CS
particles were placed on a rotating mixer for 24 hours. The size of the CS particles was
measured before centrifugation (§C). The supernatant was then removed and the CS
particles were resuspended in either 1mL PBS (pH 7) or sodium citrate buffer (pH 5).
Size measurements for the supernatant; as well as, the resuspended CS particles at t= 0, 1
and 4 hours were taken measured (§B). In between time intervals, CS particles were
placed in an incubator. It is also important to note that CS particles were redispersed by
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pipetting up and down several times before every size measurement. For further
procedural step clarification see Figure 11.

BSA Solution: Dissolve BSA in D.I. water at a 2.5
mg/mL concentration. Used for both methods.

Method 1 (Before): 0.125 % Heppe
Medical CS dissolved in D.I. water with
an acetic acid concentration 1.75 times
that of the CS concentration. Mix 0.125
mg/mL BSA into CS solution.

Method 2 (After): 0.125 %
Heppe Medical CS dissolved in
D.I. water with an acetic acid
concentration 1.75 times that of
the CS concentration.

TPP Solution: Dissolve
TPP (w/v) at a 0.5 %
concentration in D.I. water.

CS Particles: Sonicate solutions at a
1:3.5 (TPP:CS) ratio

Method 2 (After): Add 0.125
mg/mL BSA to CS particle
solution. Mix for 24 hours.

Figure 11 - BSA Before and After Chitosan Particle Encapsulation Methods
It is important to note that release of BSA from Heppe Medical Chitosan particles was
completed using a BCA assay; however, the sodium citrate interfered with the assay
causing erroneous results. Therefore, they will not be presented in this paper even though
some release was seen in PBS (pH 7) (data not shown).
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J. NAGase Release From Chitosan Particles
The release study was done to show the efficacy of CS particles as a protein
carrier for NAGase (Sigma Aldrich, St. Louis, MI). 0.390 mL of NAGase (1 mg/mL) was
dialyzed in D.I. water for 12 hours using a slide-A-Lyzer Mini Dialysis unit with a
MWCO cutoff of 3.5 kDa (Thermo Scientific, Rockford, IL). It is important to note that
the 0.390 mL was divided into separate microdialyer wells. Dialysis was important for
removing the ammonium sulfate; in which, the NAGase is dissolved in since it causes the
chitosan solution to aggregate. In order, to determine the concentration of the amount of
NAGase recovered, the dialyzed solution’s weight was measured and it was assumed that
1 µL=1 mg. From there 0.240 mg of the NAGase recovered was mixed into 5 mL of the
0.125 % CS Heppe Medical solution. The rest of the NAGase was retained for controls
and the standard curve. The CS particles were composed of 0.1 % TPP pH 4.5 and 0.125
% CS250 solution (§A). CS particles without NAGase were also fabricated as a control.
Each CS particle sample was then divided into 1.5 mL microcentrifuge tubes and
centrifuged as described in section C (§C). The supernatant was then removed and saved.
The CS particles were then resuspended in 1 mL of PBS (pH 7) or sodium citrate buffer
(pH 5). Each sample was than divided into 100 µL and placed within a 96 well plate for
an n=5 with each well correlating to a time point of 0, 1, 2, 4 and 8 hours. The
concentration of NAGase of the supernatant and at samples at different time points was
determined with a NAGase activity kit (Sigma Aldrich, St. Louis MI). The assay protocol
was completed as recommended by the manufacturer for a 96 well plate. The NAGase
activity kit is based on the hydrolysis of 4-Nitrophenyl N-acetyl-β-D-glucosaminide (NPGlcNAc) by NAGase. The enzymatic hydrolysis of the substrate releases p-nitrophenol,
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which upon ionization in basic pH can be measured colorimetrically at 405 nm. It is
important to note that studies were done to confirm that the activity of NAGase after
dialysis was not changed (data not shown). In order to correlate activity to a NAGase
concentration, a standard curve was employed. It is important to note that a standard
curve was carried out for NAGase suspended in PBS (pH 7) and sodium citrate (pH 5).

K. Statistical Analysis
For statistical analysis of the size, zeta potential, centrifugation, swelling,
encapsulation and release studies, Microsoft Excel and Minitab were used to find
averages and standard deviations. The software packages were also used to create graphs.
For comparisons among different parameters and studies t-tests and ANOVA was utilized
with a p-value of less than 0.05 being significant. Finally, for imaging studies Image J
(NIH) was utilized to determine size and polydispersity.
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III.

RESULTS AND DISCUSSION

The following sections detail the results and discussion of the different procedures
performed to characterize and optimize the CS particles as a drug delivery system for a
biofilm degrading enzyme, NAGase. This is important because biofilms are one of the
main causes of antibiotic resistance in CRBSIs, which results in increased mortality and
morbidity of critically ill patients. It was proven that CS particles can be fabricated within
a nano-sized range through DLS and SEM; therefore, making them optimal to penetrate
the biofilm for effective delivery of NAGase. The associated zeta potential was also
found to be positive, which confirms the mucoadhesive properties of chitosan. Thereby,
potentially helping to increase the residence time of the CS particles within the biofilm.
High speed centrifugation was also determined as the best method of CS particle
separation for use in other studies. However, the centrifugation procedure did show the
poor mechanical properties of the CS particles as described in the literature. Therefore,
different crosslinkers, such as sodium citrate, GPTMS and genipin, were experimented
with to try to increase the CS particles mechanical strength. It was also later found that
reducing the pH of the TPP solution to 4.5 helped decrease the size and polydispersity of
the CS particles; therefore, increasing reproducibility. Next, the pH dependent swelling
properties of the CS particles were confirmed with the lower pH resulting in faster swell
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rates. Finally, encapsulation and release of BSA and NAGase from the CS particles was
confirmed; however, the values were often low. Therefore, more optimization and
characterization is needed. Taking all the results into consideration, CS particles exhibit a
good potential as a drug delivery system to degrade biofilms for treatment of CRBSIs.

A. Fabrication of Chitosan Particles
It was found that through the ionic gelation method, CS particles were fabricated
instantaneously. This was due to the ionic bonds forming between the amino groups of
the chitosan and the negatively charged phosphates of the TPP. Figure 12 below
represents a gross imagine of Heppe Medical CS particles taken by SEM. The size and
polydispersity will be discussed later.

Figure 12 - SEM Image of Heppe Medical Chitosan Particles
1. Size Measurement of Chitosan Particles
a. Low Molecular Weight Chitosan Particles. CS and TPP concentration were
varied; in order, to determine the optimal range needed to fabricate CS particles with
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desired nanometer diameter features. From the literature, it was seen that different
concentrations of CS and TPP determined the sizes of CS particles fabricated (Calvo,
Remunan, J.L.V., & Alonso, 1997). It was observed that the smallest average diameter,
236.9 ± 38.8 nm, was obtained from the concentrations of 0.25% (w/v) CS and 0.25%
(w/v) TPP (Figure 13 and Table II). As CS concentration increased, higher TPP
concentrations were needed to produce smaller CS particles. However, if too high of a
TPP concentration was used, larger average diameters (0.25 % and 0.5 % CS) resulted,
most likely due to the repulsion of charges since there are more cations available. The 1
% CS was the exception for there appeared to be little variation in average diameter no
matter the TPP concentration. The smallest particles for 1 % CS were found at 1 % TPP,
1239.3±419.9 nm. The last important thing to notice was that the variation in data was
smaller for lower CS and TPP concentrations (Figure 13).
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Figure 13 - Size of Chitosan Particles Based on Varying Concentrations (w/v) of LMW
CS and TPP
TABLE II
AVERAGE SIZE OF CS-TPP PARTICLES (nm)
LMW CS Concentration
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TPP Concentration
0.10%
0.25%
0.50%
1%
2%

0.25%
0.50%
1%
2%
335.8±41.8
695.7±20.2
2049.3±38.8 6805.7±626.3
236.9±38.8
635.1±79.8
2011.3±133.9
8640±1812
9317±2164.2
404.5±13.2
2376±237.8 12770±2130.3
11456.7±820.4 5790±4434.3 1239.3±419.9
6291±903.3
12668.9±571.9 5813.7±4002.5 2847.7±436.2 3556.3±467.77

The study was repeated to further evaluate the correlation of LMW CS and TPP
concentrations; in addition, to particle size. The study was specifically repeated for CS
and TPP concentrations between 0.25 – 0.5 % w/v and 0.1 and 0.5 % w/v, respectively
(Table III). The data showed that the studies were not statistically different, as the p-value
was always greater than 0.05.
TABLE III
COMPARISON OF AVERAGE DIAMETER OF LMW CHITOSAN PARTICLES
First Study
CS %
TPP %
Size (nm)
Second Study Size (nm)
0.25
0.1
311.8±26.1
335.8±41.8
0.25
0.25
186.2±9.8
236.9±38.8
0.5
0.1
640.1±34.1
695.7±20.2
0.5
0.25
540.3±37.5
635.1±79.8
0.5
0.5
311.5±35.4
404.5±13.2
1
1
997.6±117.9
1239.3±419.9

It was determined the final concentrations would be 0.5 % LMW CS and 0.5 %
TPP for all subsequent studies due to its smaller CS particle size, smaller CS particle size
deviation and theoretical ability to encapsulate more NAGase due to longer chitosan
chains (Table III). The average diameters were also less than 1 µm, 311.5 ± 35.4 and
404.5 ± 13.2, meaning they should be able to diffuse through the fluid filled channels of
the biofilms (Drury, Stewart, & Characklis, 1993). As mentioned in the introduction, this
is extremely important to treat CRBSIs, since the bacteria that cause these infections
produce a biofilm, which acts as a protective matrix against antibiotics. Therefore, if
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these CS particles could not enter the channels they would not be able to specifically
deliver the enzyme to degrade the biofilms.
b. High Molecular Weight Chitosan Particles. In order to encapsulate a protein, it
is assumed that a higher molecular weight chitosan would be needed, since there should
be more linear CS chain length for the protein to get trapped in. Therefore, an additional
study was completed to determine the concentrations for HMW CS and TPP
concentrations needed to fabricate optimal sized particles (Figure 14 and Table IV).
However, the CS particle diameters were far greater than in the previous studies where
LMW CS was used. An explanation for the high particle size was that the chitosan was
forming fibers, in addition to CS particles, as observed under light microscopy.
Therefore, either the concentration of TPP needed to be increased/decreased or the
molecular weight of the chitosan decreased in order to have better ionic interactions. To
have more control over the diameter, chitosan produced within narrower manufacturing
guidelines, such as deacetylation degree and molecular weight was purchased for further
studies.
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Figure 14 - Size of Chitosan Particles Based on Varying Concentrations (w/v) of HMW
CS and TPP
TABLE IV
AVERAGE SIZE OF HMW CS-TPP PARTICLES (NM)
HMW CS Concentration
TPP Concentration
0.125%
0.25%
.5%
250.7±206.3
304.9±44.1 2099.9±2217.6
1.5 %
189.6±81.7
143.7±83.2
163.7±20.8
2%
249.5±77.1
305.7±157.3
168.9±92.3
2.5 %

c. Heppe Medical Chitosan Particles. Three different parameters were analyzed;
in order, to determine the optimal production zone of CS particles. The three parameters
included: molecular weight of chitosan (CS150, CS250, CS350 kDa), CS concentrations
(0.125, 0.25, 0.5 and 1 %) and TPP concentration (0.1, 0.25 0.5, 1.0 and 1.5 %). It was
observed that the 1 % CS250 and CS350 was too viscous and when mixed with TPP it
automatically caused the chitosan to aggregate. Therefore, these values are not included
in the following figures. As can be seen in the chart below the average diameter was
again very large as compared to the HMW CS particles. CS fibers were again confirmed
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via light microscopy.
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Figure 15 - Size of Chitosan Particles Based on Varying Concentrations (w/v) of Heppe
Medical CS and TPP
Based on this data, further studies were conducted, which included a 0.125 % CS
solution at the varying molecular weights and a 0.1 or 0.25 % TPP solution. For all
formulations with TPP concentrations equal to 0.25 %, it was observed that chitosan
fibers were still being formed via light microscopy. As the TPP concentration decreased,
the number and size of the fibers also decreased. However, CS particles without fibers
was seen when composed of a 0.1 % TPP and 0.125 %, CS250 solutions. These CS
particles had an average diameter of 198 to 226 nm (Table V). In addition it was
observed that these particles had a moderate polydispersity of 0.262-0.475, which is
typical of natural made polymers.

45

TABLE V
AVERAGE SIZE FOR 0.125 % CS + 0.1 % TPP
MW (kDa)
Size (nm)
CS150
198.5 ± 13.3
CS250
212.1 ± 32.2
CS350
226.1 ± 20.3

When analyzing the size distribution of the CS particles among the different
molecular weights the smallest variation in CS particle diameters was found to be the
lower molecular weight CS150 (Figure 16). However, the earlier issues about the ability to
encapsulate protein are still pertinent. Therefore, the CS250 was used in future studies,
since the average diameter was not statistically different from other CS molecular
weights.
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Figure 16 - Size of Chitosan Particles Based on Varying Concentrations (w/v) of Heppe
Medical 0.125 % CS and TPP
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d. Different pH TPP Solution Effect on Chitosan Particle Size. The pH of the
TPP solution was reduced in later studies based on literature that stated the CS particle
size would decrease. By adjusting the pH of the TPP solution before mixing with LMW
CS, one can modulate the concentration of anions which in turn can influence the
interaction between the TPP and CS. By adjusting the pH between 4 and 9 (native
concentration of TPP in water), it was observed that the average size of the CS particles
formed can change. It is important to note that the original pH of the TPP solution was
approximately pH 9. As seen in Figure 17, the TPP solution adjusted to pH 4.5 exhibited

Average Particle Size (nm)

the smallest average diameter CS particle (318.0 ± 32.7 nm) with little variability.
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Figure 17 - Average Size of Chitosan Particles Based on Varying pH of TPP Solution
A lower TPP solution pH needs to be maintained, since at higher pH’s the size
starts to increase. This is due to the competing hydroxyl and phosphoric ions that are
trying to interact with the amine sites of the chitosan. But at lower pH’s the hydrogen
ions are either interacting with the phosphoric ions or repelling the amine sites of
chitosan. Hence, at a certain midpoint the pH will have an optimal amount of ions from
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the TPP to interact with the amine sites of the chitosan to form CS particles. It is expected
that the Heppe Medical Chitosan particles will act in a similar manor since the same
chemistry is still being utilized.
2. Zeta Potential Measurement of Chitosan Particles

The zeta potential measurement is important for several reasons. First it confirms
the mucoadhesive properties of chitosan. This is important because the residence time of
the CS particles is increased at the biofilm; therefore, it is possible for longer NAGase
release to occur. Secondly, knowing the charge can also help determine how the NAGase
or BSA is interacting with the CS particles during encapsulation and release studies.
Thirdly, knowing the charge can help explain swelling characteristics, especially when
placed in buffers with different pH’s. Fourthly, the charge can affect the interaction
between CS particles. For example, the more negatively or positively charged the CS
particles are then the more they will repel each other. Finally, the zeta potential can help
determine the stability of the CS particles.
a. Low Molecular Weight Chitosan Particles. The zeta-potential was measured in
conjugation with the LMW CS size study at time point 0. The results are shown in Table
VI.
TABLE VI
ZETA POTENTIAL (mV) OF LMW CS-TPP PARTICLES
LMW CS Concentration
TPP Concentration
0.25%
0.50%
1%
2%
0.10%
37.8±1.1 38.4±2.1 35.4±5.4
34.3±6.5
0.25%
20.33±.7 37.93±2.5 38.47±1.7
31.5±6
0.50%
5.86±.5
19.7±.5
37.5±1.6
19.93±6.8
1%
2.91±.1
7.37±.6
25.47±2
-7.71±10.1
2%
3.21±6.4 6.64±7.4 -2.02±.9
-3.3±1.4
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The results show that as the concentration of TPP increases the zeta potential decreases.
As the concentration of CS increases the zeta potential increases. Meaning, that both
trends are a result of there being either more or less negatively charged, phosphate
groups, of the TPP or positively charged, amino groups, of the CS particles. Hence, at
certain TPP and CS concentrations there will be complete ionic interactions; however, if
either concentration is increased or decreased there will be a charge excess. This is better
shown in the interaction plot of Figure 18.
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Figure 18 - Zeta Potential at Varying Concentrations of Chitosan and TPP
In conjugation with the previous study, zeta potential was also found during the
second size study. The table below shows both studies had similar zeta potentials with no
significant statistical difference. The zeta potential for the chosen optimal, CS particles
composed of 0.5 % TPP and 0.5 % LMW CS solutions was between 19.7-22 mV.
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TABLE VII
AVERAGE ZETA POTENTIAL (mV) OF CHITOSAN PARTICLE COMPARISON
CS %
TPP %
First Study Size (d*nm)
Second Study Size (d*nm)
0.25
0.1
37.8±1.1
37.5 ±3.9
0.25
0.25
20.3±0.7
19.9±1.1
0.5
0.1
38.4±2.1
39.9±1.3
0.5
0.25
37.9±2.5
37.8±1.0
0.5
0.5
19.7±0.5
21.7±1.3
1
1
25.5±1.0
33.4±1.7

Lastly, the zeta potential was recorded overtime during the first swelling study.
This was important to establish the stability of the CS particles overtime. It was observed
that while in buffered solution the zeta potential of the particles did not change overtime
(p > 0.05) (Table VIII). However, there was significant difference (p =0.000-0.014) in
D.I. water between Day 1 and 10, Day 1 and 29 and Day 10 and 29. This difference could
be because DI water was not buffered; therefore, the components can disassociate readily
hence changing greatly the zeta potential overtime. Also it is important to note that at pH
5 the zeta potential is close to neutral pH since the buffer is more likely reaching the CS
particles isoelectric point.
TABLE VIII
ZETA POTENTIAL (mV) OVER TIME
Time Point Taken
Solvent
Day 1
Day 4
Day 10
Day 29
D.I. Water 32.8±.6 18.6±7.8 26.2±0.6
27.7±0.4
pH 7
13.3±2.3 13.2±1.1 13.4±2.4
14.5±1.9
pH 5
3.0±0.2 2.9±0.7 2.8±0.4
2.9±0.1
pH 2
12.2±8.8 15.4±2.4 19.2±4.5
18.2±1.8

b. Heppe Medical Chitosan Particles. The zeta potential for the CS particles made
with Heppe Medical chitosan is listed in Table IX. It is important to note the CS particles
were composed of 0.1 % TPP pH 4.5 and 0.125 % CS250 solutions. The average zeta
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potential was 33.9 ± 2.8 mV, which was comparable to the LMW CS particles. The
positive charge was expected due the higher concentration of CS as compared to the TPP
being used; as well as, as the low pH environment that the CS particles are fabricated in.
TABLE IX
ZETA POTENTIAL HEPPE MEDICAL CHITOSAN PARTICLES
Sample #
Zeta Potential (mV)
1
32.2
2
32.3
3
37.1

The zeta potential measurements taken show a trend based on the concentration of
CS and TPP used. For the main CS particles used the zeta potential was found to be
positive. This will allow for the CS particles to be mucoadhesive. It was also found for
the LMW CS particles that they were stable over time when placed in a buffered solution.
It was also determined that the buffer’s pH affects the zeta potential of the CS particles.
Finally, knowing the charge should help provide insight as to how the NAGase and BSA
interact with the CS particles in encapsulation and release studies.
3. Determination of Chitosan Particle Separation Method
Determining the best procedure for CS particle separation is critical for several
reasons. The main reason is to remove them from the fluid they were fabricated in. This
will be important so that they can be used for future studies in which they will need to be
resuspended in different fluids. The solution they were fabricated in might also have
unnecessary artifacts that could interfere with future tests such as assays or when drying
the CS particles for SEM. Secondly, CS particle separation could be critical for future
storage when they might need to be suspended in sucrose for freezer storage, etc. Thirdly,
separation is important in order to concentrate the particles for a higher amount of them.
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a. Low Molecular Weight Chitosan Particles. Two different methods were tried
for CS particle separation, including rotary evaporation (rotavap) and high speed
centrifugation. The rotavap method showed no statistical difference between the size
before and after the liquid has evaporated (Table X). However, due to the low volumes of
CS particles normally produced (approximately 7 mL), the set-up proved too complicated
and the entire process was very time consuming. There were also a lot of steps between
the dialyzing and actual rotavap procedure that make it highly possible there was a
significant loss of CS particles.
TABLE X
ROTAVAP LMW CHITOSAN PARTICLE AVERAGE DIAMETER (NM)
CS %
TPP %
Before Rotavap
After Rotavap
0.5
0.5
327.6±14.9
302.1±3.9
0.25
0.25
216.5±12.1
329.6±48.4

Therefore, high speed centrifugation was pursued. The original CS particle
diameter size was 320.2 ± 34 nm. The results (Table XI) show that centrifugation at
18,510 x g’s for 30 minutes at 10 °C was found to have the smallest diameter increase of
approximately 20.7 %. It is also important to note that the CS particles were also
centrifuged for 10 minutes but the time was too low for proper separation (data is not
shown). It was determined that as centrifugation times and speeds increase, aggregation
starts to occur as seen in CS particles centrifuged at 28,903, 39,830 and 51,430 x g’s
(Table XI). The aggregation is most likely a result of the poor mechanical properties of
the CS particles. Therefore, future studies were completed that looked at different
crosslinkers and changing pH’s of solutions to increase mechanical strength. Lastly, in
Table XI it can be seen that CS particles were centrifuged with and without glycerin. The
glycerin was used to try to prevent CS particle centrifugation. However, it was
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determined to have little effect as the size between both groups is not statistically
different. For all studies performed with 0.5 % TPP and 0.5 % LMW CS, the
centrifugation parameters will be 18510 x g’s for 30 minutes at 10 °C.
TABLE XI
PARTICLE SIZE (NM) 0.5 % CS-0.5 % TPP FOR 30 MINUTES AT 10 °C
Speed (g)
No Glycerin
Glycerin
1950
886.7
647.5
8230
622.4±14.1
642.2±47.9
12860
559.2
518.3
18510
443±13.3
468.3±7.4
28930
879.3±75.5
1182.7±210.9
39830
939.5
719.4
51430
3144.7±258
3550±366.4

A change was made in the fabrication process, in which genipin was added to the
CS particles as a second crosslinking agent to increase mechanical strength of the
particles (Note: For additional information on the explanation of genipin use see Section
B on different crosslinkers.) The pH of the TPP solution was also changed to 4.5, to
control the number of protonated ions on the TPP to fabricate smaller CS particles with a
tighter polydispersity. It should be of note that studies just crosslinked with genipin and
no change in pH of the TPP solution are shown in section B crosslinker studies. As
mentioned previously, genipin was added to change the mechanical properties of the CS
particles; therefore, the first centrifugation times and speeds were no longer acceptable.
When the study was repeated it was found that the CS particles spun at 40,000 x g’s for
30 minutes at 10 °C showed the smallest increase in CS particle diameter size as
compared to the original diameter (See Table VII). It should be noted that LMW CS
particles centrifuged at approximately the same time and speed had an increase in size of
approximately 200 nm (See Table XI and Table XII). A trend is also shown for the 30
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minute centrifugation time, in that as centrifugation speeds increase the diameter
increases. This trend is not apparent for the 60 minute centrifugation time. The increase
in centrifugation speed was expected because the changes in the fabrication process
helped to increase the surface mechanical strength with further crosslinking. Based on the
following data all CS particles composed of a 0.5 % TPP pH 4.5 and 0.5 % LMW CS
solutions crosslinked with 0.5-1 mM genipin solution will be centrifuged at 40,000 x g’s
for 30 minutes at 10 °C.
TABLE XII
CENTRIFUGATION STUDY WITH GENIPIN
% Increase in Size
Centrifugation Force
Average Size
from Before
(g's)
Time (minutes)
(d*nm)
Centrifugation
0
Before Centrifugation
0
336.3 ± 22.3
41.3
40000
30
572.5 ± 49.5
50.4
20000
30
678.0 ± 78.8
57.7
10000
30
794.9 ± 155.6
49.1
40000
60
660.3 ± 68.2
45
20000
60
611.1 ± 72.4
47.8
10000
60
644.8 ± 106.4

b. Heppe Medical Chitosan Particles. For the Heppe Medical Chitosan particles,
composed of 0.1 % TPP and 0.125 % CS250, a centrifugation study needed to be repeated.
This was due to the different type of chitosan being used; as well as, CS and TPP
concentrations. The following speeds and times were chosen based on previous studies.
The initial size before centrifugation was 212.1 ± 23.2 nm for 30 minutes and 262.3 ±
42.6 nm for 60 minutes. It can be seen in Figure 19 that there was an increase in average
size of the particles that were centrifuged for 30 minutes at all speeds. The same trend for
the 60 minute time interval was followed until the centrifugation speed of 39,830 x g’s;
however, due to error seen in the standard deviation the trend could still persist. It is also
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important to note that the CS particle size after centrifugation is within the range of the
CS particle sizes before centrifugation. Based on this data all CS particles composed of
Heppe Medical Chitosan at a 0.1 % TPP and 0.125 % CS solution will be centrifuged at
39,830 x g’s for 60 minutes at 10 °C.
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Figure 19 - Centrifugation Study for Heppe Medical Chitosan
As mentioned previously, the best method for CS particle separation was high
speed centrifugation. However, times and speeds varied greatly, depending on the CS
particle fabrication process. It is important to note that no one centrifugation time and
speed resulted in ideal conditions. Meaning, not all of the CS particles were removed
from the supernatant and the pellet of CS particles was not easily resuspendable if at all.
The main limiting factor for not achieving ideal separation was due to the poor
mechanical strength of the CS particles; therefore, new methods to look at increasing
mechanical properties of the CS particles needs to be completed. However, it was proven
that CS particles can be separated, which is extremely important for future swelling and
release studies.
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4. Morphological Characterization of Chitosan Particles
a. Low Molecular Weight Chitosan Particles. Morphological features were
characterized using SEM. The size of the LMW CS particles in the SEM images were
measured using Image J and were compared to DLS techniques (Table XIII). It was seen
that the diameters were of comparable diameter.
TABLE XIII
CHITOSAN PARTICLE SIZE COMPARISON BETWEEN SEM AND DLS
MEASUREMENTS
CS % TPP %
SEM Size (nm)
DLS Size (nm)
0.25
0.25
182.66
236.87
0.5
0.5
328.47
404.5
1
1
978.01
1239.3

For the 0.25 % TPP-0.25 % CS the particles formed larger non-spherical
aggregates (Figure 20). These formations could be a result of there being more chitosan
than TPP so they didn’t fully crosslink. For the 0.5 % TPP-0.5 % CS particles they are
spherical and the size is more uniformly distributed (Figure 21). Lastly, for the 1 % TPP1 % CS particles there appeared to be a larger distribution of the diameters of CS
particles; however, that could be due to the lower magnification (Figure 22). It is also
important to note that there is a residue circling the dried CS particles, which is probably
an artifact from the air drying process.
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Figure 20 - SEM Image of Chitosan Particles (0.25 % TPP-0.25 % LMW CS)

Figure 21 - SEM Image of CS Particles (0.5 % TPP-0.5 % LMW CS)
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Figure 22 - SEM Image of CS Particles (1 % TPP-1 % LMW CS)
b. Heppe Medical Chitosan Particles. To determine the morphological
characteristics of Heppe Medical Chitosan Particles, SEM imagines were again taken
(Figure 23). However, this time a different microscope was utilized, which exhibited a
better resolution of 2 µm. The average size, found manually using Image J, from three
different imagines was 332.8 ± 52.9 nm. This was comparable to the average size of
315.2 nm found via DLS. The polydispersity was also found to be 29.9 ± 2.8 %, which is
well within the acceptable range of natural polymers. Lastly, the images show that the CS
particles are spherical.
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Figure 23 - SEM Image of Heppe Medical Chitosan Particles
5. pH Swelling Study Effect on Chitosan Particles
In order to describe the release profile of the encapsulated protein, swelling
studies were performed. The desired profile includes a burst release in low pH (pH 5)
environments, but controlled release in neutral environments. The release is required at
pH 5 or lower due to the bioactivity of the enzyme of interest, NAGase. The release
profiles were compared to buffered environments at pH 2 and 7, as well as, in D.I. water.
a. Low Molecular Weight Chitosan Particles. The first swelling study involved
LMW CS particles, which were placed in 3 different pH buffers and D.I. water as a
control (See Figure 24). The CS particles size before centrifugation was 503.9 nm and
after was 871.5 ± 66.2 nm. The control showed that there was no swelling over time and
the diameters of the CS particles were similar to the diameters of those after
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centrifugation (Table XI). This is due to the similarity of the D.I. water to the solution
that the CS particles were first fabricated in.
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Figure 24 - Chitosan Particle Diameter During the First 24 Hours

The CS particles suspended in PBS (pH 2) showed a noticeable decrease in CS particle
diameter size at hour 0, which remained constant over time. This significant size decrease
was probably caused by the total dissolution of CS particles at time point 0. The CS
particles resuspended in sodium citrate (pH 5) showed an immediate increase in diameter,
which slowly decreased over time eventually plateauing at around 3000 nm. The CS
particles resuspended in PBS (pH 7), initially swelled at 5000 nm, followed by a dramatic
increase to 23810.6 nm at hour 4. However, within 24 hours the CS particles began to
shrink and plateau around 48 hours to 3500 nm (Figure 25).
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Figure 25 - Chitosan Particle Diameter Over 1 Month

b. pH Back Titration Study. For the pH back titration study it was found that CS
particles swell rapidly in sodium citrate buffer (pH 5), followed within 10 minutes by
PBS (pH 7). For the CS particles resuspended in PBS (pH 8), the size remained similar to
the size of the CS particles measured before centrifugation, showing no swelling. When
the CS particles are resuspended in PBS (pH 7) and then the pH is adjusted no reversible
trend is seen. The CS particles whose solution was adjusted to pH 5 do not show a similar
increase in size as compared to the CS particles that were immediately resuspended in
sodium citrate buffer (pH 5). This may be due to the fact that the CS particles suspended
in PBS (pH 7) have already undergone rapid swelling as seen in the change in size from 0
minutes to 10 minutes in Table XIV below. Therefore, the swelling has already greatly
increased the surface area of the CS particles, thereby exposing their ionic bonds even
more so that when the pH is adjusted lower, dissolution is actually occurring. Lastly, for
the CS particles resuspended in PBS (pH 7) whose pH was adjusted to 8 showed that
swelling that had already occurred is not reversible. However, it did appear that further
swelling was prohibited in that the size did not reach the diameter of the CS particles
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whose pH was adjusted to 5. It is important to note that this study was important to try to
establish if the CS particles had an exact pH at which they swell or don’t swell. It appears
that it may be so but more future work at varying pH’s needs to be completed.
TABLE XIV
pH BACK TITRATION STUDY
Name
Average (nm)
Before Centrifugation
238.4
pH 5 resuspended
4578
pH 7 resuspended
831.8
pH 8 resuspended
231.9
pH 7 adjusted to pH 5 (0.01 N HCL)
2011.33
pH 7 Adjusted to pH 5 w/ Sodium Citrate
2921
pH 7 10 minutes after resuspended
3152
pH 7 adjusted to pH 8 (0.01 N NaOH)
1356.5

Stdev (nm)
13.0
540.8
344.7
33.4
244.1
N/A
420.3
191.6

B. Modulation of Chitosan Particles Via Crosslinking
The addition of different crosslinkers was applied for two main reasons. The first
reason was to try to reduce CS particle aggregation during centrifugation by increasing
the mechanical strength with different crosslinkers and techniques. The second reason
was to try to better control the swelling and protein release properties of the CS particles
in different pH environments. Therefore, centrifugation and swelling studies were
completed to determine how the different crosslinkers affected these CS particle
characteristics.

1. Trisodium Citrate
The first additional crosslinker added was sodium citrate (Figure 26), which
crosslinks through ionic interactions similar to TPP (Shu & Zhu, 2002).
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Figure 26 - Chemical Structure of Trisodium Citrate
The sodium citrate was mixed directly into the TPP solution at the same 0.5 %
concentration. The initial diameter before centrifugation of the CS particles fabricated
only with TPP was 239.3 nm. When sodium citrate was added the average diameter
increased to 451.65 ± 80.1 nm. It is theorized the increase in diameter was due to further
ionic crosslinking of still exposed positive chitosan amino groups.
A study on the swelling properties of CS particles crosslinked with the sodium
citrate was completed immediately after fabrication and 24 hours later in solutions of
various pH. As seen in Table XV, there was an initial swelling at hour 0 for D.I. Water,
pH 7 and pH 5 with a slow degradation at hour 24 (Table XV). It is also important to note
that there is rapid degradation of CS particles in the low pH of PBS (pH 2). Lastly, a
general linear ANOVA showed a significant difference between the effect of buffers on
swelling.
TABLE XV
SWELLING RESPONSE OF CHITOSAN PARTICLES CROSSLINKED WITH
SODIUM CITRATE
Buffer
Hour 0 Size (nm)
Hour 24 Size (nm)
D.I. Water
2526.333±242.3
1798.667±436.6
pH 7
2013.333±855
1972.333±793.2
pH 5
2316.667±605.4
1265.667±166.6
pH 2
426.367±22.7
369.600±17.7

63

2. GPTMS
In other studies, GPTMS (Figure 27) was also used as a covalent crosslinker
because of its proven biocompatibility. It has also been used in other studies, in addition
to TPP. In that study, it was proved that CS particles can still be fabricated using the
same mild, spontaneous fabrication process, with retention of pH dependent swelling
properties (Pan, Wu, & Wu, 2009).

Figure 27 - Chemical Structure of GPTMS
In this study GPTMS was introduced during or after the addition of TPP to the
CS solution. The initial size of CS particles when GPTMS was added after ionic gelation
fabrication was 394.4 ± 27.8 nm. When GPTMS was added alongside the TPP the initial
size of CS particles was 322.3 ± 2.9 nm. Compared to CS particles that were allowed to
swell in D.I. water there was a marked increase in diameter in buffers at pH 7 and pH 5.
As previously seen with the sodium citrate crosslinked CS particles, the GPTMS particles
also instantly degraded in low pH 2. As can be observed in Table XVI, there was a
significant difference in swelling when comparing the timing of GPTMS addition (pvalue = 0.002). When GPTMS was added after ionic gelation there was a marked
decrease in diameter (9-74%) at 24 hours for particles in D.I. Water, pH 7 and pH 5
buffers. This could be a result of a two-fold swelling mechanism in that at hour 0 the TPP
ionic interactions are controlling the swelling rate. But at 24 hours GPTMS is preventing
further swelling since it crosslinks covalently.
64

TABLE XVI
CS PARTICLE DIAMETER (NM) CROSSLINKED WITH GPTMS
GPTMS During Formation
GPTMS After Formation
Buffer
Hour 0
Hour 24
Hour 0
Hour 24
D.I. Water
707.7±6.5
604.3±8.5
621±39.4
298.8±8.5
pH 7
1293.2±666.4
2756±612
2496.3±73.5
1055.1±612
pH 5
3119.7±1654.1 2660.3±894.1 4381.3±1273.7 1123.7±894.1
pH 2
362.7±1210.6
292±22.4
340.1±54.5
371.9±22.4
3. Genipin
The last crosslinker tested was genipin (Figure 28). It was used because it has
been proven in numerous literature reports to be 5,000-10,000 times less cytotoxic than
glutaraldehyde (Sung, Huang, Huang, & Tsai, 1999). It has also been used to make
chitosan microparticles (Mi, Sung, Shyu, Su, & Peng, 2003).

Figure 28 - Chemical Structure of Genipin
The genipin was also added either during or after ionic gelation of the chitosan to
TPP. It is important to note that just genipin and chitosan solutions did not form CS
particles. The initial size of the CS particles before centrifugation when genipin was
added alongside TPP was 372.4 ± 9.8 nm and when genipin was added after TPP was
326.8 ± 74.3 nm. The timing of when genipin was added was a significant factor in
determining CS particle size (p-value = 0.008). When the genipin was added after ionic
gelation there was rapid swelling in pH 7 and pH 5 buffers followed by continued
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swelling at hour 24. However, when the genipin was added before ionic gelation there
was an initial swelling followed by degradation. The difference in swelling profiles is due
to the method, in which genipin crosslinks the chitosan (Table XVII). For instance, when
genipin is added after ionic gelation it is mainly crosslinking the outer surface of the
particles; whereas, genipin added before ionic gelation is crosslinking the same amines as
TPP, both the inner and outer diameter of the particles. Therefore, the CS particles,
whose outer surface is crosslinked with genipin has an additional cage to take further
swelling stresses. It is important to note that CS particles in low pH buffer (pH 2) were
rapidly degraded at hour 0, again following the same swelling trends noted in the sodium
citrate and GPTMS studies.

Buffer
D.I. Water
pH 7
pH 5
pH 2

TABLE XVII
GENIPIN CROSSLINKING STUDY
Genipin After Particle Formation
Genipin During Particle Formation
Hour 0 (nm)
Hour 24 (nm)
Hour 0 (nm)
Hour 24 (nm)
459.3 ± 6.3
392.4 ± 8.3
708.9 ± 207.7
599.3 ± 150.6
2279.3 ± 548.4
5938.3 ± 279.7
3124.7 ± 1381.3
2431.3 ± 473.2
3606.3 ± 136.4
5247.3 ± 577
2590 ± 693
1806 ± 279.6
332.3 ± 22.6
227.4 ± 12.3
431.8 ± 62.1
343.267 ± 8.7

As previously shown, pH of the TPP solution can have an effect on the size of the
CS particles formed. Hence, the size of CS particles were re-examined twice with the pH
of the TPP solution adjusted to pH 4.5 with genipin crosslinking. The study showed no
significant difference (p-value = 0.281) of CS particle size between experiments
performed on different days (Table XVIII).
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Name
D.I. Water
pH 7
pH 5

D.I. Water
pH 7
pH 5

TABLE XVIII
GENIPIN CROSSLINKER STUDY (TPP ADJUSTED TO pH 4.5)
Genipin During Particle Formation
Genipin After Particle Formation
Hour 0
Hour 0
Experiment 1
Experiment 2
Experiment 1
Experiment 2
718.2 ± 192.7
726.6 ± 46.5
575.2 ± 29.7
616.4 ± 18.1
251.5 ± 12.9
950 ± 521
1040.4 ± 823.3
858.5 ± 446.5
2173.7 ± 1334.3
3244.3 ± 618.5
4596.7 ± 687.8
6259.3 ± 1836.5
Hour 24
Hour 24
Experiment 1
Experiment 2
Experiment 1
Experiment 2
591.1 ± 155.3
619.2 ± 12.5
416.1 ± 35.4
491.6 ± 23.4
222.8 ± 17.7
1907.9 ± 1645.2
3857.7 ± 836
1760 ± 915.6
5266.7 ± 1111.5
5243 ± 1090.7
3598.3 ± 793.9
5058.3 ± 817.6

The table below (Table XIX) lists an overall view of the crosslinker studies for
comparison. These characteristics included the original size before and after
centrifugation; as well as, the swelling profile. From the table it was gathered that CS
particles crosslinked with genipin after ionic gelation with TPP at pH 4.5 provided the
necessary CS particle characteristics. Meaning, CS particle’s diameter was nano-sized.
The CS particles also showed a higher swelling rate in pH 5 than pH 7 at hour 0, which
should better correlate to release of NAGase in the appropriate pH environment.
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TABLE XIX
OVERALL CROSSLINKER STUDY
Hour 0

Name

0.5 %
CS +
0.5 %
TPP

0.5 %
CS +
0.5 %
TPP +
0.5 %
Sodium
Citrate

0.5 %
CS +
0.5 %
TPP + 5
%
GPTMS
Before

0.5 %
CS +
0.5 %
TPP + 5
%
GPTMS
After

0.5 %
CS + 0.5
% TPP
(pH 9) +
0.5 mM
genipin
Before

0.5 %
CS + 0.5
% TPP
(pH 9) +
0.5 mM
genipin
After

0.5 %
CS + 0.5
% TPP
(pH 4.5)
+ 0.5
mM
genipin
Before

0.5 % CS
+ 0.5 %
TPP (pH
4.5) + 0.5
mM
genipin
After

Original Size
Before
Centrifugation

503.9

451.7

394.4

322.3

372.4

285.3

468.7

299.1

Supernatant

N/A

202.3

188.5

121.6

181.9

121.9

368.4

92.7

D.I. Water

871.48

2526.3

707.7

621

708.9

459.3

722.4

595.8

pH 7

4563.4

2013.3

1293.2

2496.3

3124.7

2279.3

600.75

949.45

pH 5

16912.8

2316.7

3119.7

4381.3

2590

3606.3

2709

5428

pH 2

360.46

426.4

362.7

340.1

431.8

332.3

N/A

N/A

Hour 24
D.I. Water

702.6

1798.7

604.3

298.8

599.3

392.4

605.15

453.85

pH 7

14738.6

1972.3

2756

1055.1

2431.3

5938.3

1065.35

2808.85

pH 5

3934.8

1265.7

2660.3

1123.7

1806

5247.3

5254.86

4323.3

pH 2

315.8

369.6

292

371.9

343.3

227.4

N/A

N/A

4. Heppe Medical Chitosan Crosslinked With Genipin
For the Heppe Medical chitosan, the effects of genipin both on initial size and
centrifugation needed to be study. Centrifugation was important as genipin was added to
increase the mechanical properties of the particles. However, its effects were different, as
compared to the LMW CS crosslinked with genipin. In fact the data showed that the
genipin did not contribute any significant mechanical strengthening properties to the CS
particles as seen in Figure 29 below, even when the pH of the TPP solution was changed.
Therefore, the addition of genipin was no longer needed in the Heppe Medical chitosan at
the new CS and TPP concentrations.
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Figure 29 - Heppe Medical Chitosan Particles Crosslinked with Genipin Study

C. Protein Delivery
I.

BSA Encapsulation in Chitosan Particles
To determine how much protein is encapsulated within the LMW CS particles,
the encapsulation efficiency was calculated for various starting concentrations of BSA.
The amount encapsulated was determined by the amount of BSA remaining in the
formulation buffer after CS particle formation. This concentration was determined
spectroscopically (@ 280 nm) or using a protein quantification assay. It can be seen in
Figure 30 that 0.25 mg/mL BSA had the highest encapsulation efficiency of 61.1 ± 35.4
%. However, a paired t-test showed no statistical difference between any of the BSA
concentrations. Hence, there appears to be no trend of BSA concentration vs.
encapsulation efficiency within this range.
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Figure 30 - BSA Encapsulation Efficiency Performed Spectroscopically
A BCA protein quantification assay was also used for encapsulation efficiency
due to its increased sensitivity. The data shows that the encapsulation efficiencies were a
lot higher, with 0.5 mg/mL encapsulated BSA exhibiting the highest rate of encapsulation
efficiency as seen in Figure 31. However, again there was no statistical difference
between the BSA encapsulated concentrations. It is also important to note that 2 mg/mL
encapsulated BSA was not included in this analysis due to its high signal saturating the
plate reader. It is hypothesized that the higher encapsulation efficiencies could be due to
the higher sensitivity of the BCA assay. When comparing the encapsulation efficiencies
of BSA to NAGase they were found to be similar, equaling approximately 90 %.
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Figure 31 - BSA Encapsulation Efficiency Study Performed Via BCA Assay
In order to visualize protein encapsulated within the CS particles, confocal
microscopy was used to image BSA conjugated to FITC within the nanoparticles formed
with HMW CS. It can be seen in the images (Figures 32 and 33) that BSA was
encapsulated within the CS particles using either method. However, it is also important to
note that fibers were observed; however, they did not appear to be encapsulating BSA.
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Figure 32 - Confocal Image Encapsulating BSA After Chitosan Particle Formation

Figure 33 - Confocal Image Encapsulating BSA Before Chitosan Particle Formation
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BSA Release From Chitosan Particles
a. Low Molecular Weight Chitosan Particles. In order to understand the drug
release from pH dependent CS particles, a swelling study was performed, which
encapsulated BSA. Initially, CS particles encapsulating BSA were smaller than the CS
particles not encapsulating BSA. They all appear to follow the same trend of having a
maximum release at hour 1 (Figure 34 and 35). However, the CS particles encapsulating
BSA in PBS (pH 7) did have a steady release from hour 1 to hour 4; instead, of a swelling
rate decline. However, it is difficult to confirm that it is not following the same trend due
to the large standard deviation. Comparing the data without BSA to the previous study,
shows similar hour 1 swelling sizes but this study has less of a pronounced increase at
hour 1. Overall, this data shows a greater swelling of CS particles in pH 5. This is
desired; in order, to have a burst release of the NAGase into a pH 5 environment where it
has optimal activity.
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Figure 34 - Swelling Study of Chitosan Particles Encapsulating BSA

73

Size (d*nm)

Swelling Study
5000
4500
4000
3500
3000
2500
2000
1500
1000
500
0

pH 7
pH 5
Initial Size

0

1

2

3

4

5

Time (hours)

Figure 35 - Swelling Study of Chitosan Particles Not Encapsulating BSA
The release of BSA from LMW CS particles is reported in Figure 36. It is
important to note that 1 mg/mL BSA was dissolved in the CS solution before CS particle
formation. In this formulation, BSA release was not detectable until 24 hours; however,
given the large standard deviation the statement may be false. In addition, there was no
difference seen between the different pH environments. The delayed release is most
likely due to the genipin crosslinking the BSA instead of just the chitosan. From this
study it was determined that the encapsulation method of the BSA needed to be further
explored; as well as, a more optimal measurement system that is not as affected by
chitosan. Therefore, BSA will be encapsulated after CS particle formation if using
genipin and a fluorometer will be used to measure BSA concentration.
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Figure 36 - Release Study of Chitosan Particles Measured Spectroscopically
In the next release study, BSA conjugated with FITC was encapsulated after CS
particle formation at a concentration of 0.25 mg/mL. The encapsulation efficiency was
approximately 79.3 ± 4 %. The study showed a positive release for every time point but
the BSA release rate was extremely low compared to the encapsulation efficiency (Figure
37). Also the release profiles were extremely different for both buffers and do not follow
the swelling trends. There is also no clear distinction in which buffer showed a higher
BSA release rate. Lastly, with the BSA being encapsulated afterwards there is no burst
release and the release rate appears to be reaching 0 within 8 hours.
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Figure 37 - Release Study of Non-Stirred BSA Measured by Fluorometer
The next release study was similar to the previous study; however, the sample was
continuously stirred at room temperature and only 0.125 mg/mL BSA was encapsulated.
The encapsulation efficiency was 37.1 ± 18.1 %, meaning 0.046 mg/mL was
encapsulated. When looking at hour 0 (Figure 38) approximately 4 % of the BSA that
was encapsulated was released. This is most likely just the BSA loosely encapsulated on
the surface being removed for measurement. After hour 0 there appears to be no release
in sodium citrate buffer while BSA release in pH 7 remains constant.
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Figure 38 - Release Study of Stirred BSA Measured by Fluorometer
Compared to the first fluorometer study that was not stirred the BSA release was
approximately 30 % lower. This was expected due to the difficulty of establishing a
standard curve of BSA+FITC. Therefore, more studies must be done to optimize BSA
release but what is important is that both exhibited a burst release in a pH 5 buffer. This
is important as it relates to a specific aim of the project, which is the CS particles provide
a burst in a pH 5 environment so that NAGase is within its optimal activity range.
b. Heppe Medical Chitosan Particles. The next swelling study was performed
using Heppe Medical Chitosan. Figure 39 shows a significant increase in CS particle
diameters in sodium citrate buffer (pH 5) at hour 0 when compared to pH 7. The diameter
of the CS particles in sodium citrate buffer than drastically decreases to match the CS
particles suspended in PBS (pH 7). It was also observed that the encapsulation method of
the enzyme, whether it is before or after CS particle formation, does not affect the
swelling size of the CS particles. As time increases it is expected, based on previous
results (data not shown) that the CS particles will remain the same size. Lastly, the
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swelling behavior at pH 5 is desired, since an increase in CS particle diameter should
correlate to a burst release of the NAGase. This is again desired because the main release
will occur within the target that is the biofilm and in an environment at which NAGase
has optimal activity.
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Figure 39 - Heppe Medical Chitosan Particle Swelling Study
For release of BSA from Heppe Medical Chitosan particles a BCA assay was
completed; however, due to the molarity of the sodium citrate buffer it had a negative
reaction with the kit (data not shown). Therefore, future studies could reduce the molarity
of the sodium citrate to levels the BCA assay kit can handle or find a new pH 5 buffer
system. It is important to note that a fluorometer release study was not pursued to the
difficultly of establishing a standard curve.

III.

NAGase Release from CS Particles
In the NAGase release study, the encapsulation efficiency was calculated to be
88.89 ± .36 % but only 1 % of the NAGase was released within 8 hours. While the
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therapeutic dose to degrade the biofilm is not yet established it is hypothesized that this
amount of release it too low. The graph also does not correlate to the high concentration
burst release of NAGase needed. The study also showed higher release at hour 0 followed
by a decrease in release at each time point until stabilization at hour 4 was established
(Figure 40). As expected, due to the swelling studies, the release rate of NAGase is
higher for CS particles suspended in sodium citrate buffer (pH 5) as compared to those
suspended in phosphate buffer saline (pH 7). However, the release profile does not follow
the expected trend in that the release starts to decrease after hour 0. This was not
expected because CS encapsulated NAGase particles were immediately resuspended in a
buffer and then divided into 100 µL for each time sample; therefore, the curve should
remain the same as hour 0 or the release should increase overtime. Possible reasons as to
why this might occur; include, the protein adsorbing to the plate it is contained in or the
NAGase using chitosan as a substrate instead of the 4-Nitrophenyl N-acetyl-β-Dglucosaminide substrate that is used to determine NAGase activity. However, the
important objective of this study was proven in that there was release of the NAGase but
then must be optimized in future studies.
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Figure 40 - NAGase Release Study
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IV.

CONCLUSIONS

The research showed that CS nanoparticles can be created through ionic
crosslinking with a polyanion, tripolyphosphate. When developing the CS particles as a
drug delivery vehicle for a biofilm degrading enzyme, NAGase, it was important that the
following parameters be optimized, including: size of CS particles, pH dependent
swelling properties of CS particles, encapsulation efficiency of NAGase and release
kinetics of NAGase. These parameters were important to optimize for the function of the
CS nanoparticles. Meaning, they must be small enough to fit within the voids and
microchannels of the biofilm. They must also exhibit a pH controlled release of NAGase
that is activated by the lower pH waste pockets of the biofilm. Finally, NAGase release
must be established so that it can start to degrade biofilms.
For the CS particles to fit its function, the following parameters were optimized
through design of experiments that looked at the concentration of CS and TPP solutions
used during particle fabrication, the molecular weight of chitosan used, deacetylation %,
pH of TPP solution, etc. Another measurement conducted was the zeta potential of the
CS particles, which showed they exhibit a positive charge, reaffirming its mucoadhesive
properties. The best separation method was found to be high speed centrifugation. The
times and speeds were later optimized to achieve the highest CS particle efficiency
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return. However, it was shown through high speed centrifugation that the CS particles
have low mechanical strength. Therefore, studies examining different crosslinkers were
conducted, such as genipin. Several different imagining techniques were also done to
confirm that the CS particles were approximately 200-400 nm in diameter and were
spherical in shape with a small polydistribution. As mentioned earlier, the pH dependence
of the CS particles was established but the sensitivity at pH 5 and pH 7 differed little.
Encapsulation was also proven via confocal microscopy and assays with both a model
protein BSA and NAGase. Finally, release of BSA and NAGase was shown at both pH 5
and pH 7. In conclusion, the concept for developing CS nanoparticles to deliver a biofilm
degrading enzyme, NAGase, was established; however, future work to better optimize
and prove its efficacy still need to be determined.
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V.

RECOMMENDATIONS

While the concept to develop CS particles encapsulating NAGase for biofilm
degradation was proven there are still several parameters that must be optimized. These
parameters; include, increasing mechanical properties of the CS particles, better tailoring
pH-dependent swelling properties for targeted release, and showing higher release of
NAGase. In addition, better imagining is also needed; in order, to view the size, shape
and morphology of the CS particles. Finally, release of the NAGase from CS particles
must also be proven to cause biofilm degradation. It is the ultimate goal that this drug
delivery system can be used alongside an antibiotic releasing silk catheter coating.
The first parameter that needs to be better optimized is the mechanical strength of
the CS particles. There was some work into this area through the addition of crosslinkers,
such as sodium citrate, GTPMS and genipin, with genipin showing the best results.
Unfortunately, due to time the genipin coating was never fully optimized for the Heppe
Medical Chitosan. Therefore, this path should be continued with particular focus on only
crosslinking the outside membrane of the CS particles. With this technique it will be
important to reestablish swelling and release profiles with and without the use of the
genipin coating. If no improvement in mechanical strength is seen during the
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centrifugation process then moving to a different CS particle fabrication process, such as
single emulsion or nanoprecitation might be pursued.
The second parameter that needs to be optimized is the pH-dependent swelling
properties of the CS particles. This parameter is critical because the entire drug delivery
system is dependent on having a controlled release of the NAGase due to changes in pH
of the biofilm microenvironments. In this study, which used ionic gelation to create CS
particles, it was found that the pH triggered release mechanism was not as specific for pH
5 as was described in the literature. Meaning, CS particles suspended in pH 7 also
showed increased swelling, which quickly reached the same swelling levels as pH 5
within 15 minutes of each other. However, when CS particles were suspended in a pH 8
solution, no swelling occurred. This showed that the CS particles could be controlled via
a pH change but the specific pH value at which swelling is triggered still needs to be
better established. Answering this question is essential because the CS particles need to
retain most of their payload until they reach the appropriate target. Methods to improve
swelling rates rely heavily on understanding the underlying chemical kinetics. Therefore,
attention must be paid to the pH and concentration of the TPP and CS solution before
nanoparticle fabrication; as well as, what is occurring during the ionic gelation process. If
this cannot be better controlled, a different CS particle fabrication process might need to
be pursued.
The third parameter that needs to be optimized is the release of NAGase from CS
nanoparticles. In this paper, it was shown that the encapsulation efficiency of NAGase in
CS particles was roughly 90 %. However, in a NAGase release study it was shown that
only 1 % of the NAGase was released within 8 hours. While the therapeutic index has not
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yet been established for biofilm degradation, the amount released in hour 1 is most likely
too low. Therefore, a better understanding of why the release is low needs to be
determined. Possible answers; include NAGase absorbing to the plate during the release
study or NAGase using chitosan as the substrate instead of the substrate found within the
activity kit. It will be essential to demonstrate a higher release of NAGase from CS
particles before studies involving actual biofilms can be completed.
Due to a combination of factors CS particles were often difficult to image. The
main reason was due to the polymeric nature of CS particles, meaning there were fewer
to no electrons to excite. Different methods to improve this, such as gold sputter coating,
phosphotungstic staining and copper TEM grids were also tried with no results. Another
reason for the difficultly in imagining was because the CS particles had to be dried before
first, which caused clumping and crystallization of the sample to occur. Methods such as
rotary evaporation, vacuum drying and critical flash dryer were tried to reduce the drying
effects with no results. Another problem resulted from using lower concentrations of CS
and TPP solutions during particle fabrication because they showed a lower CS particle
fabrication efficiency. This made it difficult to image individual particles via methods
like AFM even when centrifugation was done. Lastly, problems with the resolution of the
equipment, especially the SEMs, also occurred due to the small size of the CS particles.
One method that provides promise for future SEM and TEM imagining is graphene
support TEM films because they have a lower dynamical interference; thereby, reducing
background noise. The second promising technique for future confocal imaging is the use
of FluoromountG from Southern Biotech. This product is a thick, viscous substance that
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helps to diminish the photobleaching of the fluorescence’s while helping the CS particles
to better retain their structure during the drying process.
Lastly, it is important to show that the CS particles encapsulating NAGase
degrade biofilms through a pH dependent release. Once proven, the therapeutic dosage
must be established. Once characterization of drug delivery system is completed within
the in-vitro model, it will need to be joined to antibiotic containing silk film. The in-vitro
work must then be repeated again to prove that there is a decrease in antibiotic resistance.
In conclusion, this paper proves that the initial design is possible for this
particular application. It is also important to note that through the course of research a lot
more questions were raised that still need to be answered; in order, to optimize and prove
the efficacy of the design. However, by answering all the questions mentioned above a
better and more tailored drug delivery vehicle can be created.
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